Skip to content
Screener

Krystal Biotech, Inc. KRYS Q2 2025 earnings

Reported August 4, 2025 · Before market open

Revenue$96.0MBeat by $627.3K
EPS$1.29Beat by $0.21
Revenue estimate$95.4M
EPS estimate$1.08

Next report

Nov 2, 2026 (in a month)
Revenue estimate$129.1M
EPS estimate$1.91

Financials

Q2 2025

Income statement

See full
Revenue$96.0M+36.6%
Operating income$39.3M+359%
Net income$38.3M+146%
EPS (diluted)$1.29+143%

Balance sheet

See full
Cash & equivalents$353.8M+2.3%
Total debt$9.7M+25.9%
Total equity$1.0B+24.1%
Total assets$1.1B+24.1%

Cash flow

See full
Operating cash flow$52.7M—
CapEx$1.9M+68.3%
Free cash flow$50.8M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$4.15B-20.1%
Enterprise value$3.81B-21.6%
P/E28.3×-20.8×
P/S11.6×-19.7×

Profitability

See full
Operating margin38.8%+30.5pp
Net margin40.8%-22.9pp
FCF margin51.6%+44.2pp

Returns & leverage

See full
Return on equity15.6%+1.4pp
Debt / equity0×0.0×
Current ratio9.7×+0.2×

FAQ

When did Krystal Biotech, Inc. report Q2 2025 earnings?
Krystal Biotech, Inc. (KRYS) reported Q2 2025 earnings on August 4, 2025 before market open.
What were Krystal Biotech, Inc.'s Q2 2025 revenue and EPS?
Krystal Biotech, Inc. reported revenue of $96.0M and eps of $1.29 for Q2 2025.
Did Krystal Biotech, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $95.4M by $627.3K. EPS beat the consensus estimate of $1.08 by $0.21.
How did Krystal Biotech, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.6% from $70.3M a year earlier and eps grew 50.0% from $0.86.
Where can I find Krystal Biotech, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001711279-25-000078) and the 10-Q periodic report (0001711279-25-000077) directly on SEC EDGAR. The filing index links above go to sec.gov.